Down-regulation of fibroblast growth factor 2 and its co-receptors heparan sulfate proteoglycans by resveratrol underlies the improvement of cardiac dysfunction in experimental diabetes

Autor(es)

Cassaro Strunz, Celia Maria ; Roggerio, Alessandra ; Cruz, Paula Lazara ; Pacanaro, Ana Paula ; Cury Salemi, Vera Maria ; Benvenuti, Luiz Alberto ; Mansur, Antonio de Padua ; Irigoyen, Maria Claudia

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF NUTRITIONAL BIOCHEMISTRY; v. 40, p. 219-227, FEB 2017.
• Citações Web of Science: 4

Resumo

Cardiac remodeling in diabetes involves cardiac hypertrophy and fibrosis, and fibroblast growth factor 2 (FGF2) is an important mediator of this process. Resveratrol, a polyphenolic antioxidant, reportedly promotes the improvement of cardiac dysfunction in diabetic rats. However, little information exists linking the amelioration of the cardiac function promoted by resveratrol and the expression of FGF2 and its co-receptors, heparan sulfate proteoglycans (HSPGs: Glypican-1 and Syndecan-4), in cardiac muscle of Type 2 diabetic rats. Diabetes was induced experimentally by the injection of streptozotocin and nicotinamide, and the rats were treated with resveratrol for 6 weeks. According to our results, there is an up-regulation of the expression of genes and/or proteins of Glypican1, Syndecan-4, FGF2, peroxisome proliferator-activated receptor gamma and AMP-activated protein kinase in diabetic rats. On the other hand, resveratrol treatment promoted the attenuation of left ventricular diastolic dysfunction and the down-regulation of the expression of all proteins under study. The trigger for the changes in gene expression and protein synthesis promoted by resveratrol was the presence of diabetes. The negative modulation conducted by resveratrol on FGF2 and HSPGs expression, which are involved in cardiac remodeling, underlies the amelioration of cardiac function. (C) 2016 The Authors. Published by Elsevier Inc. (AU)

• Processo FAPESP: 12/20262-7 - Ação do resveratrol sobre proteoglicanos de membrana presentes no músculo cardíaco em modelo animal de cardiomiopatia diabética
• Beneficiário: Celia Maria Cassaro Strunz
• Modalidade de apoio: Auxílio à Pesquisa - Regular